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Abstract Cancer cachexia is a multifaceted syndrome
characterized, among many symptoms, by extensive muscle
wasting. Chronic systemic inflammation, partly triggered and
sustained by cytokines, as well as increased oxidative stress
contributes to the pathogenesis of this complex metabolic
disorder. L-carnitine plays a central role in the metabolism of
fatty acids and shows important antioxidant and anti-
inflammatory properties. Systemic carnitine depletion has
been described in several diseases, and it is characterized by
fatigue, muscle weakness, and decreased tolerance to
metabolic stress. In cachectic cancer patients, low serum
carnitine levels have been reported, and this change has been
suggested to play an important contributory role in the
development of cachexia. Based on these data, carnitine
supplementation has been tested in preliminary studies
concerning human cachexia, resulting in improved fatigue
and quality of life. We present here a review of clinical and
experimental evidence regarding the use of carnitine supple-
mentation in the management of cancer cachexia.
Keywords L-carnitine.Cachexia.Cancer.Fatigue
1 Introduction
Cancer cachexia is a paraneoplastic syndrome present in 80%
of terminally ill patients [1–3] and is markedly associated
with adverse prognosis and shortened survival time [4, 5].
The symptoms include anorexia, weight loss, muscle loss,
skeletal muscle atrophy, anemia, and alterations in carbohy-
drate, lipid, and protein metabolism [6]. Perhaps, one of the
most relevant characteristics of cachexia is fatigue, which
reflects the extensive muscle wasting associated with
syndrome [5, 7, 8]. Actually, body protein depletion is one
of the main trends of cachexia and involves not only skeletal
muscle but also cardiac proteins, resulting in alterations in
heart performance. This complex metabolic disorder is
accompanied by an increase in local and systemic inflam-
matory mediators, such as proinflammatory cytokines [e.g.,
interleukin (IL)-6 and IL-8 and tumor necrosis factor-alpha
(TNF-α)] [9, 10]. Another potential mediator is the
imbalance of endogenous anabolic hormones (e.g., testoster-
one, insulin-like growth factor 1) and catabolic factors, such
as glucocorticoids and myostatin [9, 11]. Moreover, tissue
sensitivity to insulin is considerably reduced [12], and
cellular prooxidant–antioxidant homeostasis is also disturbed
with enhanced susceptibility to oxidant-induced stress [13].
Carnitine, a trimethylated amino acid roughly similar in
structure to choline, facilitates the transfer of activated
long-chain fatty acids from the cytoplasm to the mitochon-
dria, where they are processed by oxidation to produce ATP
[14]. It is involved in the transfer of the products of
peroxisomal beta-oxidation to the mitochondria and in the
removal of short-chain and medium-chain fatty acids from
these organelles, in which it is responsible for maintaining
coenzyme A levels. Carnitine thus plays a central role in the
metabolism of fatty acids and energy by regulating the
mitochondrial ratio of free coenzyme A to acyl-coenzyme
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DOI 10.1007/s13539-011-0017-7A. Approximately 75% of carnitine in the organism is
derived from dietary source [15], and red meat and dairy
products are particularly rich in the amine, while 25% is
synthesized in the liver and kidneys, from lysine and
methionine [16]. The skeletal muscle and myocardium are
carnitine-dependent, since they rely upon fatty acid oxida-
tion as the main source of energy.
Patients with cancer are especially at risk for carnitine
deficiency. They frequently present decreased caloric intake
and increased metabolic requirements. In addition, pharma-
cological therapy interferes with carnitine absorption,
synthesis, and excretion [17, 18]. The early studies by
Winter et al. [19] reported carnitine deficiency in patients
with chronic illness, including cancer. Recently, other
studies have reported low serum levels of carnitine in
cancer patients [20–25].
L-Carnitine supplementation has been shown to improve
the patient’s condition in several diseases, including senile
dementia, metabolic neuropathies, HIV infection, myopa-
thies, cardiomyopathies, and renal failure [26, 27]. In
experimental cachexia, carnitine supplementation signifi-
cantly lowered the tumor-induced rise in triacylglycerol, as
well as cytokine production [28]. We have recently found
that L-carnitine supplementation improves liver lipid me-
tabolism of tumor-bearing rats (submitted data). The gene
expression of microsomal triglyceride transfer protein, and
carnitine palmitoiltransferase (CPT I) catalytic activity are
reduced in the liver of cachectic rats, which also show
increased liver (150%) and plasma (3.3-fold) triacylglycerol
content. L-carnitine supplementation (1 g/Kg/d) was able to
reverse the reduction of CPT I catalytic activity, recovering
liver metabolic capacity. Based on these data, carnitine
supplementation has been tested in preliminary studies on
human cachexia. We present here a review on clinical and
experimental evidence concerning the use of carnitine
supplementation in the management of cancer cachexia.
2 Muscle atrophy and cancer cachexia
Chronic systemic inflammation, triggered and sustained by
cytokines as well as increased oxidative stress, contribute to
thepathogenesisofcachexia.Skeletalmusclelossrepresentsa
key feature of cachexia, and recently, the advances in the field
of molecular biology have shed light on the pathogenesis of
this symptom. Recent findings indicate that muscle-specific
genes (i.e., myosin heavy chain) and their products must be
targeted to initiate muscle wasting [29]. Muscle atrophy
occurs at different levels, starting from repressed gene
expression, ending with accelerated protein degradation.
Myogenesis is severely compromised, and disruption of
sarcomere architecture is associated with proteolysis of
contractile apparatus [12]. Furthermore, the studies show
that, besides myofibrilar protein loss, apoptosis is also
present in skeletal muscle of cachectic tumor-bearing
animals [30] and human patients with cancer cachexia [31].
When loss of skeletal muscle is grounded by chronic
inflammatory disease or cancer, the level of inflammatory
cytokines is markedly elevated [32, 33]. For long, it has
been known that TNF-α is the most prominent among them
[34, 35], and some authors have reported that TNF-α is
able to induce muscle protein loss [36, 37] and skeletal
myocyte apoptosis both in vivo and in vitro [38, 39].
Figueras et al. [40] showed that, during experimental
cachexia, the contribution of muscle-derived TNF-α is
decreased; however, significant changes were observed in
relation to TNF-α receptors at the skeletal muscle level that
could possibly be related with muscle wasting associated
with tumor growth. Recently, it was shown that, in the
skeletal muscle of cachectic patients, there is increased
expression and activity of TNF-α-related pathways, includ-
ing TNF-α mRNA, activation of TNFR1, and TNF-α
associated to TNFR1, and increased oxidative stress [41].
3 Trophic effect of L-carnitine on skeletal muscle
The muscle is the most prominent carnitine depository
since it stores about 95% of the total carnitine contained in
the adult human body, showing a concentration 70-fold
greater than that of the plasma. Carnitine is critical for
normal skeletal muscle bioenergetics [42], and indeed,
skeletal muscle is greatly affected in states of carnitine
deficiency.
We investigated the influence of different doses (0.1, 1.0,
and 2.0 g/kg/day) and time intervals (1, 14, or 28 days) of
oral L-carnitine supplementation upon plasma and muscle
L-carnitine concentration, as well as upon some aspects of
lipid metabolism in rats (submitted data). The highest
increase of plasma L-carnitine was found in the groups
supplemented for 14 days with 1.0 and 2.0 g, compared
with the controls. On the other hand, the highest alteration
in muscle L-carnitine content was found in the groups
supplemented for 28 days with 0.1, 1.0, and 2.0 g. These
results indicate that no proportional relationship can be
found between plasma and muscle L-carnitine concentration
and that the lowest dose (0.1 g) supplemented for 28 days is
already able to induce the maximal muscle concentration.
Therefore, supplementation with higher doses is not
necessary to enhance muscle content. Furthermore, even
increases over 120% of muscle L-carnitine concentration
were not able to modify long-chain fatty acid uptake, fat
content, and carnitine palmitoyltransferase I and II (CPT I
and II) activity in the skeletal muscle of control animals.
Some studies have shown that L-carnitine may present an
important role in the treatment of the myopathy induced by
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of L-carnitine (2 g/day) to patients undergoing hemodialysis
resulted in increased serum and muscle carnitine levels,
together with hypertrophy and predominance of type I
fibers [43] in the muscle. Another study [44] with uremic
patients with some degree of muscular atrophy, reports that
24-week treatment with L-carnitine (2 g IV at the end of
hemodialysis, or in dialysis solution, or per os twice daily)
leads to an increase of about 7% in the diameter of type I
and type IIa fibers, as well as to a reduction in atrophic
fibers. No remarkable changes were documented in type IIb
fibers [44]. These findings suggest a specific effect of
L-carnitine on type I and IIa fibers, which are characterized
by predominant oxidative metabolism and therefore require
carnitine for fatty oxidation to produce energy.
4 Carnitine and oxidative stress
It has been widely shown that clinically significant
oxidative stress takes place in patients with advanced
cancer, as shown by augmented levels of reactive oxygen
species (ROS) and decreased levels of glutathione perox-
idase [45, 46]. Moreover, cancer-related anorexia/cachexia
syndrome and oxidative stress alone or in combination are
highly predictive of clinical outcome and survival [47, 48].
In skeletal muscle, ROS and nitrogen species are normally
synthesized at low levels and are required for normal force
production [49]. However, at high levels, they may suppress
tissue antioxidant capacity, thus leading to oxidative stress.
Oxidative imbalance is involved in several models of cancer-
induced cachexia [50–52], and proteins are major targets of
oxidative stress-derived effects on tissues [50, 53]. It was
recently suggested that the ROS cascade regulates patho-
physiologic signaling, leading to proteolysis and apoptosis,
when these factors are present at high levels within
myofibers [54]. Moreover, many studies suggest that
cachexia is associated with a decrease in intracellular
glutathione concentration in the muscle [55–57]. Decreased
glutathione levels and increased glutathione disulphide/
glutathione ratios have been observed in the skeletal muscle
of weight-losing tumor-bearing mice [57]. L-carnitine treat-
ment improved the tumor-induced decrease in muscular
glutamate and glutathione levels and the increased plasma
glutamate levels in tumor-bearing rodents [55].
Gramignano et al. [58] studied the efficacy of L-carnitine
supplementation in a population of advanced cancer
patients. L-carnitine administration (6 g/day for 4 weeks)
led to a decreased ROS and increased glutathione peroxi-
dase level, but not to a significant extent. However, other
studies have demonstrated important effects of L-carnitine
on oxidative stress, as in patients with renal disease [59],
phenylketonuria [60], and nonalcoholic steatohepatitis [61],
as well as on several experimental models of oxidative
stress [62–64].
5 Carnitine and fatigue
Fatigue is the most common symptom experienced by
patients with cancer [65]. Up to 80% to 96% of patients
receiving chemotherapy and 60% to 93% of patients
receiving radiation therapy report significant fatigue [66].
Only recently fatigue has been included among the most
important symptoms in cancer patients, and its evaluation is
still not routinely included among the symptoms attribut-
able to the toxicity of chemotherapy [67]. There are
multiple potential predisposing/etiologic factors, including
cancer itself, treatment-related adverse effects, physiologic
complications, impaired performance status, and psycho-
logical comorbidities, such as depression [65, 67]. Besides,
tumor-induced cytokines and host-produced proinflamma-
tory cytokines may represent a possible mechanism
contributing to fatigue [68].
Recent research shows that some anticancer drugs
interfere with carnitine network. An initial increase in
plasma carnitine levels after initiation of chemotherapy and
the development of carnitine deficiency during treatment
with cisplatin, ifosfamide, or doxorubicin are reported [25].
The initial enhancement in plasma carnitine concentration
may be associated with rapid tissue release into blood-
stream to replace carnitine loss induced by chemotherapy
[25]. Cisplatin causes reduction in glomerular filtration and
tubular damage, and patients receiving this drug may have
an increased loss of carnitine through the kidney [69]. The
metabolic pathway of ifosfamide leads to formation of
chloroacetyl-CoA, and the presence of chloroacetyl-
carnitine is detected in urine [69]. This detoxification
results in a secondary deficiency of carnitine in patients
receiving ifosfamide. Doxor u b i c i na l s oi n f l u e n c e st h e
carnitine system by decreasing heart concentration of free
carnitine, free fatty acid oxidation, creatine phosphate, and
oxygen uptake [70]. Additionally, anticancer therapy may
affect the carnitine-dependent oxidation of fatty acids [17]
and mitochondrial function [71–74].
Taken together, these data suggest that chemotherapy-
induced damage of carnitine system and secondary defi-
ciency of the molecule may cause fatigue due to impaired
energy metabolism. Indeed, it is reasonable to hypothesize
that carnitine repletion might be an effective strategy for the
treatment of fatigue in this population.
A preliminary analysis to determine the effects of 1 week
of L-carnitine supplementation in cancer patients with
fatigue and carnitine deficiency showed a significant
improvement on fatigue, depression, and sleep disruption
[22]. A phase I/II open-label trial of L-carnitine supplemen-
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cancer reported similar results, since most of the patients
who received L-carnitine experienced improved fatigue,
mood, and sleep [75]. In another study, patients with
advanced cancer receiving chemotherapy and presenting
low levels of serum carnitine were treated with oral
L-carnitine (4 g daily for 7 days) [21]. Fatigue was
improved in the majority of patients, with the concomitant
normalization of serum carnitine levels. In addition to these
previously fatigue-related reported effects, an increase of
lean body mass and appetite were also reported, which may
explain the improvement of symptoms with respect to
fatigue and quality of life [58]. Significant improvements in
fatigue were also observed in a randomized phase III
clinical trial, in which L-carnitine (4 g/day) was orally given
to patients with advanced cancer [76].
6 Anti-inflammatory effects of L-carnitine
As previously reported, TNF-α have been implicated on the
muscle protein loss in cancer cachexia [32–34]. Steffen,
Lees, and Booth [77] reported that the administration of
either soluble TNF receptor-1 or the general inhibitor of
TNF-α production, pentoxifylline, attenuated losses in both
body and skeletal muscle mass, and also reduced increases
in ubiquitin proteasome pathway transcripts in an animal
model of cardiac cachexia.
Some findings support the hypothesis that administration
of L-carnitine attenuates the inflammatory process in patho-
logical conditions; however, there are no data on cancer
cachexia. In hypertense animals, L-carnitine supplementation
was able to counteract the enhancement of IL-1β, IL-6, and
TNF-α in the plasma and heart tissue [78]. Oral administra-
Fig. 1 Action mechanism of L-carnitine on cancer cachexia
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to a significant decrease in serum TNF-α [79]. Moreover,
studies report that L-carnitine decreases C-reactive protein, a
positive acute phase protein that is increased in inflamma-
tion, in hemodialysis patients [80, 81]. L-carnitine treatment
also was able to restore the age-related changes in the
functions of inflammatory cells, and presented a protective
role in the tissue destruction in inflammation by decreasing
the superoxide anion production [82].
Furthermore, an interesting study showed that L-carnitine
can transactivate glucocorticoid-responsive promoters in
vitro, in a way similar to dexamethasone [83], suppressing
the release of TNF-α and IL-2 by IFN-γ primed and/or
LPS-stimulated human primary monocytes. The authors
suggest that the immunomodulatory effects of L-carnitine
may, at least in part, be mediated by activation of
glucocorticoid receptor-α.
7 Safety
In most studies, a dose between 2 and 6 g of L-carnitine/day
was adopted; however, little is known about the amin’s
safety and tolerability in cancer patients. Cruciani et al. [75]
reported that L-carnitine may be safely administered orally
at doses up to 3,000 mg/day. Mild gastrointestinal effects
(nausea and vomiting) may occur. Besides, the investiga-
tions indicate that although responses are variable, blood
levels can be restored within only 1 week of supplemen-
tation, but it is unlikely that skeletal muscle levels are fully
restored by the end of this period [22, 75].
8 Conclusions and future perspectives
Since the levels of inflammatory cytokines as well as
increased oxidative stress are related to cachexia, therapeutic
strategies to ameliorate such conditions may be extremely
important to counteract these deleterious effects. There is
evidence that L-carnitine is able to reduce chronic inflamma-
tion and oxidative stress in cancer patients (Fig. 1).
Considering the positive results supported by studies, L-
carnitine appears a very interesting agent in the treatment of
cancer cachexia. However, more clinical trials are needed to
define the optimal use of L-carnitine as therapeutic agent to
improve cachexia symptoms, as muscle atrophy, fatigue, and
inflammatory/oxidative profile on cancer patients.
On the other hand, at the basic research level, it is
important to comprehensively address the molecular path-
ways involved in the effect of L-carnitine supplementation
and to extend the knowledge regarding the response of
other organs and tissues, beyond the liver and muscle. We
have shown, for instance, that the white adipose tissue,
whose morphophysiology is severely affected by cachexia,
is an important contributor to systemic inflammation during
paraneoplastic syndrome and other mild chronic inflamma-
tory diseases [84–87]. Therefore, it should be interesting to
examine the effect of L-carnitine supplementation upon
adipokines, which are not only mediators of inflammation,
but are also involved in the regulation of oxidative balance,
along with important metabolic effects.
There may also be potential beneficial effects of
L-carnitine supplementation in regard to the central nervous
system. Hypothalamic carnitine palmitoyltransferase is
involved, along with fatty acid synthase in the regulation
of the melanocortin system, and since many factors
including TNF-α and IL-1 inhibit fatty acid oxidation [88,
89], it is conceivable that L-carnitine supplementation may
affect energy intake in cachectic patients.
Taken together, the data available in the literature
indicate that L-carnitine supplementation appears as a very
interesting complementary therapy for cancer patients and
that the study of the mechanisms underlying its effects
should be carefully examined.
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